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A Small Molecule Inhibitor of PDK1/
PLCγ1 Interaction Blocks Breast 
and Melanoma Cancer Cell Invasion
Claudio Raimondi1,†, Veronique Calleja2,‡, Riccardo Ferro1, Alessandro Fantin3, 
Andrew M. Riley4, Barry V. L. Potter4,5, Caroline H. Brennan6, Tania Maffucci1, 
Banafshé Larijani2,$ & Marco Falasca1,7
Strong evidence suggests that phospholipase Cγ1 (PLCγ1) is a suitable target to counteract 
tumourigenesis and metastasis dissemination. We recently identified a novel signalling pathway 
required for PLCγ1 activation which involves formation of a protein complex with 3-phosphoinositide-
dependent protein kinase 1 (PDK1). In an effort to define novel strategies to inhibit PLCγ1-dependent 
signals we tested here whether a newly identified and highly specific PDK1 inhibitor, 2-O-benzyl-myo-
inositol 1,3,4,5,6-pentakisphosphate (2-O-Bn-InsP5), could affect PDK1/PLCγ1 interaction and impair 
PLCγ1-dependent cellular functions in cancer cells. Here, we demonstrate that 2-O-Bn-InsP5 interacts 
specifically with the pleckstrin homology domain of PDK1 and impairs formation of a PDK1/PLCγ1 
complex. 2-O-Bn-InsP5 is able to inhibit the epidermal growth factor-induced PLCγ1 phosphorylation 
and activity, ultimately resulting in impaired cancer cell migration and invasion. Importantly, we 
report that 2-O-Bn-InsP5 inhibits cancer cell dissemination in zebrafish xenotransplants. This work 
demonstrates that the PDK1/PLCγ1 complex is a potential therapeutic target to prevent metastasis and 
it identifies 2-O-Bn-InsP5 as a leading compound for development of anti-metastatic drugs.
Metastasis, the ability of cancer cells to spread from a primary site and form tumours at distant sites, is the main 
cause of death in cancer patients1. Cancer cells with high metastatic potential are characterised by high prolifera-
tion and migration2. During metastasis, malignant cells are able to “escape” from the primary tumour through the 
circulatory or lymphatic system, invading distant healthy tissues to initiate a new malignant lesion. Cell motility 
is critical for this process to occur and the mechanisms involved in regulation of cell motility are the results of 
an intricate network of signals activated by different growth factors, chemo-attractant and extracellular matrix 
(ECM) components in vivo3.
The endogenous signalling pathways associated with high metastatic potential remain unclear. Strong evi-
dence has demonstrated that activation of the enzyme phospholipase Cγ 1 (PLCγ 1) is a key and crucial step 
in metastasis development and progression3–6. PLCγ 1 is activated by integrin engagement to the ECM and it 
also plays an important role in growth factor-induced cell motility, being activated by tyrosine kinase recep-
tors such as epidermal growth factor (EGF) receptor3,5,6. Recent evidence produced by our group confirmed the 
pivotal role of PLCγ 1 in malignant cell invasion and its role in metastasis development and progression4. PLCγ 
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1 possesses a pleckstrin homology (PH) domain that can bind to the phosphoinositide 3-kinase (PI3K) lipid 
product phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] and contribute to translocation of the enzyme 
to the plasma membrane7. Our previous work demonstrated that this binding is essential for PLCγ 1 activation7 
and it is required for EGF-induced migration of breast cancer cells8 and basic fibroblast growth factor-mediated 
migration and remodelling of human umbilical vein endothelial cells9.
Deregulated PI3K signalling is very common in cancer and it leads to dysregulation of several intracellular 
processes, including cell survival, growth, proliferation and migration10,11. Among the downstream effectors of 
PI3Ks, 3-phosphoinositide-dependent protein kinase 1 (PDK1) and AKT have key roles in several cancer types12. 
PDK1 in particular is highly expressed in many human breast cancer cell lines and both PDK1 protein and mRNA 
are overexpressed in a majority of human breast cancers13,14. Overexpression of PDK1 is sufficient to transform 
mammary epithelial cells and, furthermore, PDK1 has an essential role in regulating cell migration15,16. Moreover, 
we have recently demonstrated that PDK1 can regulate PLCγ 1 activation in a mechanism involving assembly of a 
complex between the two enzymes upon growth factor stimulation17.
Similar to PLCγ 1, PDK1 possesses a PH domain and, in addition to the phosphoinositide PtdIns(3,4,5)P3, 
the PH domain of PDK1 has been shown to bind inositol phosphates such as inositol 1,3,4,5-tetrakisphosphate 
[Ins(1,3,4,5)P4] and inositol 1,3,4,5,6-pentakisphosphate (InsP5)18. Interestingly, InsP5 exhibits anti-angiogenic 
properties and it induces apoptosis in ovarian, lung and some breast cancer cell lines19,20 by preventing AKT phos-
phorylation. We have recently identified an InsP5 derivative, 2-O-benzyl-myo-inositol 1,3,4,5,6-pentakisphosphate 
(2-O-Bn-InsP5), that possesses higher pro-apoptotic activity than InsP521. Kinase profiling assay revealed that 
2-O-Bn-InsP5 specifically inhibits PDK1 in vitro in the low nanomolar range (IC50 = 26 nM). Importantly, we 
demonstrated that this compound was able to inhibit PDK1-dependent phosphorylation of AKT in cell lines and 
excised tumours21.
Here we investigated the effect of 2-O-Bn-InsP5 on the novel identified PDK1/PLCγ 1 signalling pathway and 
its mechanism of action. We show that 2-O-Bn-InsP5 binds to the PH domain of PDK1 with high affinity, as 
assessed by isothermal titration calorimetry (ITC). By binding PDK1 PH domain, 2-O-Bn-InsP5 prevents the 
formation of the PDK1/PLCγ 1 complex. This in turn results in inhibition of cell migration, 3D Matrigel invasion 
of breast and melanoma cell lines in vitro, and ultimately tumour cell dissemination in zebrafish xenotransplants.
Taken together these data demonstrate that targeting the PDK1/PLCγ 1 is a promising strategy to prevent 
metastatic dissemination. Furthermore, these data identify 2-O-Bn-InsP5 as a leading compound to develop 
anti-metastatic drugs.
Results
2-O-Bn-InsP5 is a specific PDK1 PH domain inhibitor. We have recently identified a synthetic deriva-
tive of the natural compound InsP5, named 2-O-Bn-InsP5, which potently and specifically inhibits PDK1 in vitro 
as well as the PDK1-dependent phosphorylation of AKT Thr308 in cancer cell lines and in vivo21. To further 
characterise the anti-PDK1 activity of this compound we first determined whether 2-O-Bn-InsP5 was able to 
interfere with the platelet-derived growth factor (PDGF)-induced, PDK1-dependent AKT activation. To this end, 
NIH 3T3 cells were pre-treated for 10 min with 2-O-Bn-InsP5 followed by 5 minutes stimulation with 30 ng/ml 
of PDGF (Fig. 1A) and changes in AKT conformation were monitored by a time-resolved FRET approach using 
an AKT activation sensor (eGFP-AKT-mRFP). Data revealed that PDGF treatment induced a conformational 
change in eGFP-AKT-mRFP and this was inhibited by pre-treating the cells with 2-O-Bn-InsP5 (Fig. 1A). As a 
result of this impaired conformational change, 2-O-Bn-InsP5 strongly inhibited the PDGF-induced phospho-
rylation of AKT at its residues Thr308 and Ser473 in NIH 3T3 transfected with eGFP-PDK1 and eGFP-AKT 
(Fig. 1B–D). Taken together, these data demonstrate that 2-O-Bn-InsP5 inhibits PDK1-dependent AKT phospho-
rylation and are consistent with our previous data in vitro and in vivo21.
Since it has been reported that InsP5 can bind to PDK1 PH domain we hypothesised that 2-O-Bn-InsP5 could 
inhibit PDK1 by binding to this domain and therefore interfere with its interaction with PtdIns(3,4,5)P3. To test 
this hypothesis, we determined the thermodynamic parameters of 2-O-Bn-InsP5 binding to PDK1 PH domain 
by ITC (Table 1). The closely related PH domain of AKT2 was used as a control to monitor the specificity of 
binding of the inhibitor (Supplementary Figure 1A). From four independent experiments, performed at 25 °C, 
the binding affinity of 2-O-Bn-InsP5 for the PH domain of PDK1 (Kd) was calculated to be 109 ± 44 nM with a 1:1 
stoichiometry (n = 0.90 ± 0.04) (Table 1 and Fig. 2A). Binding was driven by a favourable enthalpic contribution 
Δ Hobs = − 4.1 ± 0.5 kcal/mol and an entropic (− TΔ S) contribution of − 0.291 ± 0.002 kcal/mol. However, no sig-
nificant heat change was detected by titrating the inhibitor into the AKT2 PH domain performed at 25 °C (Fig. 2B) 
and at 15 °C indicating that the inhibitor is specific for the PDK1 PH domain. The specificity of 2-O-Bn-InsP5 
for PDK1 is consistent with our previous results from a kinase profiling assay that tested ~50 distinct kinases 
in vitro and that revealed a selective inhibition of PDK1 activity21. Importantly no direct inhibition of AKT activity 
in vitro was detected in this assay21, consistent with ITC results.
To further assess the specificity of 2-O-Bn-InsP5 in a cellular context, MDA-MB-231 cells were treated with 
2-O-Bn-InsP5 50 µM or vehicle alone before stimulation with EGF and activation of several enzymes was assessed 
using a commercially available Proteome Profiler Human Phospho-Kinase Array Kit. Out of 45 proteins tested, 
2-O-Bn-InsP5 treatment specifically affected only the EGF-induced phosphorylation of AKT, ERK1/2 and PLCγ 1 
(Supplementary Figure 1B), confirming the high specificity of this compound. Specifically, 2-O-Bn-InsP5 reduced 
the PDK1-dependent phosphorylation of AKT at its residues Thr308 and Ser473 (Supplementary Figure 1B), 
consistent with our previous data (Fig. 1B–D) and our previous report21. 2-O-Bn-InsP5 reduced phosphoryla-
tion of PLCγ 1 at its residue Tyr783 (Supplementary Figure 1B), in agreement with our previous study demon-
strating that chemical inhibition of PDK1 was able to affect the EGF-induced Tyr783 PLCγ 1 phosphorylation17. 
Validation of the Proteome Profiler Human Phospho-Kinase Array data by immunoblotting analysis confirmed 
reduced EGF-induced AKT phosphorylation but similar ERK1/2 phosphorylation in MDA-MB-231 treated with 
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2-O-Bn-InsP5 compared to cells treated with vehicle only, suggesting that 2-O-Bn-InsP5 does not affect ERK1/2 
phosphorylation (Supplementary Figure 1C). Taken together these data strongly suggest that 2-O-Bn-InsP5 spe-
cifically inhibits PDK1 activation in a mechanism involving its binding to PDK1 PH domain.
2-O-Bn-InsP5 inhibits PLCγ1-PDK1 complex formation in MDA-MB-231 breast cancer cells. It 
is well established that PDK1 is required for activation of several AGC kinases including AKT. More recently 
we demonstrated that PDK1 can also regulate activation of PLCγ 1 in a mechanism involving formation of a 
specific complex between the two enzymes17. We therefore decided to investigate whether inhibition of PDK1 
by 2-O-Bn-InsP5 might affect the formation of PLCγ 1/PDK1 protein complex. Stimulation of MDA-MB-231 
overexpressing PLCγ 1 and PDK1 with EGF for 3 minutes induced major reorganisation of the plasma membrane 
(Fig. 3A white arrows) and formation of a PDK1/PLCγ 1 complex, as demonstrated by increased steady-state 
FRET signal (Fig. 3B), as previously reported17. Treatment of MDA-MB-231 with 2-O-Bn-InsP5 inhibited reor-
ganisation of the plasma membrane (Fig. 3A) and completely blocked the EGF-induced FRET signal (Fig. 3B) 
Figure 1. PDGF-induced change in conformation and phosphorylation of AKT are inhibited upon 
treatment with 2-O-Bn-InsP5. (A) The increase in FRET efficiency upon PDGF treatment indicates a change 
in conformation of AKT that is prevented upon pre-treatment with the inhibitor. Box and whiskers plots 
of FRET efficiencies are displayed for the indicated conditions. Each cell is represented by a red symbol. A 
Mann-Whitney test was used to calculate the P values shown on the graph (n = 3 experiments; **p = 0.0016, 
***p = 0.0001). (B) Cells were left untreated or treated with 2-O-Bn-InsP5 prior to PDGF stimulation and 
phosphorylation of AKT at residues Threonine 308 (pT308) and Serine 473 (pS473) was assessed by Western 
blotting. (C,D) Results from densitometry analysis of Western blotting showing significant decrease in 
the normalized phosphorylation of AKT at T308 and S473 from 4 independent experiments (**p = 0.002, 
*p = 0.007 respectively).
n (sites) Hobs (kcal/mol) TΔS (kcal/mol) G (kcal/mol) D (nM)
0.91 − 4.897 − 0.289 − 5.186 92
0.94 − 3.769 − 0.293 − 4.062 78
0.89 − 3.816 − 0.291 − 4.107 174
0.84 − 4.005 − 0.291 − 4.296 140
0.90 ± 0.04 − 4.122 ± 0.527 − 0.291 ± 0.002 − 4.413 ± 0.525 109 ± 44
Table 1.  Summary of the thermodynamic parameters for the binding of 2-O-Bn-InsP5 to the PH domain 
of PDK1 at 25 °C.
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indicating that 2-O-Bn-InsP5 prevents the formation of the PLCγ 1/PDK1 complex (Fig. 3B). In agreement with 
results from FRET analysis, treatment with 2-O-Bn-InsP5 also reduced the EGF-induced endogenous association 
between PLCγ 1 and PDK1 detected by immunoprecipitation analysis in MDA-MB-231 (Fig. 3C). Quantification 
of the number of cells showing major membrane rearrangements and localisation of both PLCγ 1 and PDK1 at 
the plasma membrane confirmed that treatment with 2-O-Bn-InsP5 strongly inhibited the EGF-induced translo-
cation of both enzymes (Fig. 3D).
Taken together these data demonstrate for the first time that 2-O-Bn-InsP5 inhibits association of PLCγ 1 and 
PDK1 at the plasma membrane.
2-O-Bn-InsP5 inhibits the EGF-induced PLCγ1 tyrosine phosphorylation. We previously reported 
that the formation of a PDK1/PLCγ 1 complex is involved in regulation of PLCγ 1 activation17. Importantly, data 
from the phosphokinase array indicated that treatment with 2-O-Bn-InsP5 reduced the EGF-induced phospho-
rylation of PLCγ 1 at its residue Tyr783 (Supplementary Figure 1B), which is required for the enzyme activation. 
To better investigate whether the effect of 2-O-Bn-InsP5 on PDK1/PLCγ 1 complex formation results in inhibition 
of PLCγ 1 activity, MDA-MB-231 cells were left untreated or treated with 2-O-Bn-InsP5 before stimulation with 
EGF (Fig. 3E,F). The PDK1 inhibitor GSK2334470 was used in parallel in these experiments. Consistent with 
our previous results17, treatment with GSK2334470 strongly reduced the EGF-induced PLCγ 1 phosphorylation 
(Fig. 3E,F). Importantly, treatment with 2-O-Bn-InsP5 also significantly inhibited PLCγ 1 phosphorylation upon 
EGF stimulation (Fig. 3E,F, Supplementary Figure 1C). These data indicate for the first time that blockade of the 
PDK1/PLCγ 1 complex formation by 2-O-Bn-InsP5 is able to inhibit Tyr783 PLCγ 1 phosphorylation.
2-O-Bn-InsP5 inhibits the EGF-induced calcium release in MDA-MB-231 and MDA-MB-435 
breast cancer cells. To further investigate the effect of 2-O-Bn-InsP5 on PLCγ 1 signalling we next deter-
mined the effect of this compound on EGF-induced calcium release, a process dependent on PLCγ 1 activa-
tion. The parental molecule InsP5 which has a higher IC50 for PDK1 (613 nM) compared to 2-O-Bn-InsP5 
(26.5 nM)21, was used in parallel in these experiments. Consistent with our previous results17, stimulation of 
MDA-MB-231 and MDA-MB-435 cells with EGF induced a clear PLCγ 1-dependent increase of intracellular cal-
cium levels (Fig. 4A,E). Importantly, treatment with InsP5 significantly reduced the EGF-induced calcium release 
in MDA-MB-231 (Fig. 4B,D) and in MDA-MB-435 (Fig. 4F,H). Furthermore treatment with 2-O-Bn-InsP5 
completely suppressed the EGF-induced intracellular calcium increase in MDA-MB-231 (Fig. 4C,D) and 
MDA-MB-435 (Fig. 4G,H).
These data demonstrate for the first time that 2-O-Bn-InsP5 inhibits the EGF-induced PLCγ 1 activation and 
confirmed the higher inhibitory activity of 2-O-Bn-InsP5 compared to the parental molecule (Fig. 4).
2-O-Bn-InsP5 inhibits fibronectin-induced cell migration in MDA-MB-231. Our previous study 
demonstrated that the PDK1/PLCγ 1 complex is required for cancer cell migration and invasion17. Therefore, 
we next investigated whether inhibition of the complex formation and PLCγ 1 activation by 2-O-Bn-InsP5 was 
Figure 2. 2-O-Bn-InsP5 binds to the PH domain of PDK1 but not that of AKT2. (A) Titration of 2-O-Bn-
InsP5 into the PH domain of PDK1 results in a decrease in binding heats as the titration proceeds (top panel) 
giving a distinct binding isotherm (bottom panel). (B) Titration of 2-O-Bn-InsP5 into the PH domain of AKT2 
did not show decrease in binding during titration analysis. Heats corresponding to each injection are small and 
remain constant and are equivalent to the heats of dilution indicating that no binding occurs.
www.nature.com/scientificreports/
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able to affect migration of MDA-MB-231 cells. The effect of the parental molecule InsP5 was also determined 
in these experiments. Results from transwell migration assays revealed that 2-O-Bn-InsP5 completely blocked 
fibronectin-induced cell migration in MDA-MB-231 (Fig. 5A). Importantly, 2-O-Bn-InsP5 had a more potent 
inhibitory effect than InsP5 when tested at the same concentration (50 μ M) (Fig. 5A). Dose response analysis 
showed that 2-O-Bn-InsP5 was able to inhibit cell migration by 80% compared to untreated cells at a concentra-
tion as low as 10 μ M (Fig. 5B). These data demonstrate that 2-O-Bn-InsP5 inhibits cancer cell migration.
2-O-Bn-InsP5 inhibits cell invasion on Matrigel in different human and murine breast cancer 
cell lines. We next investigated the effect of 2-O-Bn-InsP5 on cancer cell invasion on Matrigel. Invasion assays 
were performed using MDA-MB-231 human breast cancer cell line, MDA-MB-435 and A375M human mela-
noma cell lines (Fig. 5C) and murine syngeneic breast cancer cell lines TSA and 4T1 (Fig. 5D). Data showed that 
2-O-Bn-InsP5 strongly inhibits Matrigel invasion in all cell lines tested. In particular, 52.7%, 63.8%, 73.9% and 
87.9% inhibition was observed in TSA, MDA-MB-435, MDA-MB-231 and 4T1 cells, respectively. Consistent with 
data on migration, 2-O-Bn-InsP5 inhibited cell invasion on Matrigel more potently than InsP5 (Fig. 5C,D). To 
investigate whether 2-O-Bn-InsP5 inhibits cancer cell Matrigel invasion by specifically inhibiting PDK1/PLCγ 1 
pathway, we performed invasion assays using A375M cells transfected with anti-PLCγ 1 specific siRNA (si-PLCγ 1) 
or a non-targeting siRNA sequence (si-control) and treated with 2-O-Bn-InsP5 or with vehicle only (Fig. 5E). 
Downregulation of PLCγ 1 reduced A375M invasion on Matrigel compared to control cells (Fig. 5E), consistent 
with our previous report17. Importantly, we observed that while treatment with 2-O-Bn-InsP5 reduced invasion 
in cells transfected with control siRNA it did not further reduce invasion in cells transfected with the siRNA tar-
geting PLCγ 1 (Fig. 5E), indicating that 2-O-Bn-InsP5 treatment has no additive inhibitory effect on cell invasion 
Figure 3. 2-O-Bn-InsP5 inhibits PLCγ1-PDK1 complex formation and PLCγ1 tyrosine phosphorylation 
in MDA-MB-231 cells. (A) Localisation of PLCγ 1 and PDK1 visualised by high definition confocal scan in 
MDA-MB-231 overexpressing PLCγ 1 and PDK1. Cells were left untreated or treated with 2-O-Bn-InsP5  
50 μM and then stimulated with EGF for 3 min. Arrows indicate plasma membrane localisation. Bar: 20 μ m. 
(B) Percentage of FRET in MDA-MB-231 cells co-expressing PLCγ 1 and PDK1 at the indicated time of EGF 
stimulation. Columns are the means ± SEM of percentage of FRET measured at protrusion level in proximity of 
the plasma membrane. (C) Endogenous PLCγ 1 and PDK1 were co-immunoprecipitated from MDA-MB-231 
untreated or treated with 2-O-Bn-InsP5 50 μM and stimulated with EGF 50 ng/ml for the indicated time points. 
PLCγ 1 was immunoprecipitated using a specific anti-PLCγ 1 antibody and association of the two enzymes was 
assessed by immunoblotting using anti-PLCγ 1 and anti-PDK1 antibodies. Parallel co-immunoprecipitation 
using mouse IgG was performed as control. (D) Percentage of MDA-MB-231 cells displaying plasma membrane 
rearrangement presenting both PLCγ 1 and PDK1 staining at the plasma membrane. Cells expressing exogenous 
PLCγ 1 and PDK1 were stimulated with EGF for the indicated times in the presence or absence of 2-O-Bn-InsP5 
50 μM. Graph shows the means ± SEM from n = 3 independent experiments. (E,F) Representative Western 
blot (E) and corresponding densitometry analysis (F) of EGF-induced PLCγ 1 tyrosine phosphorylation in 
MDA-MB-231 untreated or treated with 2-O-Bn-InsP5 50 μM or GSK2334470 1 μM. In E, GAPDH was used as 
loading control. Data in F are means ± SEM from n = 4 independent experiments. P value: *< 0.05; #≤ 0.01.
www.nature.com/scientificreports/
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in cells lacking PLCγ 1. Taken together these data demonstrate that 2-O-Bn-InsP5 is able to inhibit invasion of 
several cancer cell lines more efficiently than the parental molecule InsP5.
2-O-Bn-InsP5 does not affect cell proliferation and cell survival in MDA-MB-435, 4T1 and TSA 
cell lines. We next assessed the effect of 2-O-Bn-InsP5 on cell proliferation and cell survival. Cell counting 
assays showed that treatment with either 2-O-Bn-InsP5 or InsP5 for 72 hours did not affect cell proliferation or cell 
survival of MDA-MB-231, MDA-MB-435 and TSA cell lines (Supplementary Figure 2A–C). Similarly, no change 
in proliferation was observed in 4T1 cells treated with 2-O-Bn-InsP5 (Supplementary Figure 2D). Interestingly a 
decreased number of 4T1 cells was detected upon treatment with 2-O-Bn-InsP5 in serum free conditions.
2-O-Bn-InsP5 inhibits tumour cell dissemination in zebrafish xenotransplant. To analyse whether 
2-O-Bn-InsP5 is able to inhibit the dissemination of breast cancer cells in vivo, we used a model of xenotransplant 
Figure 4. 2-O-Bn-InsP5 inhibits EGF-induced calcium release in MDA-MB-231 and MDA-MB-435 cells. 
Calcium release assay performed in MDA-MB-231 (A–D) and MDA-MB-435 (E–H) treated with 2-O-Bn-InsP5 
and InsP5 (50 μ M). Arrows indicate the time point(s) of EGF and ATP stimulation. The chart is the mean ± SEM 
of 4 independent experiments; asterisks indicate P value; *< 0.05; **≤ 0.01.
www.nature.com/scientificreports/
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in zebrafish embryos. First, we tested 2-O-Bn-InsP5 for toxic effect on zebrafish. Importantly, no toxic effects were 
observed when zebrafish embryos were treated with 100 μ M 2-O-Bn-InsP5 as judged by comparing movement 
(Fig. 6A) and total distance (Fig. 6B) covered by untreated and 2-O-Bn-InsP5-treated larvae at day 6dpf.
Then, we injected highly metastatic MDA-MB-231 breast cancer cells stably expressing GFP into the heart22 
of 48h post fertilization Tg(kdrl:HsHRAS-mCherry)s896 zebrafish embryos, which express Cherry fluorescent pro-
tein specifically in endothelial cells. To assess the correct injection of tumour cells into the heart and/or cardiac 
chamber, zebrafish embryos were live-imaged by confocal microscopy (Fig. 6C) immediately after the injection. 
Embryos displaying a similar number and distribution of injected tumour cells were selected and randomly 
divided into a group that was left untreated and a group that was treated with 2-O-Bn-InsP5 100 μM. Then, 
after three days, zebrafish embryos were fixed, immunostained using anti-Cherry and anti-GFP antibodies and 
imaged by high resolution confocal microscopy. Embryos untreated or treated with 2-O-Bn-InsP5 showed a sim-
ilar amount of GFP-derived fluorescence (Fig. 6D). Because GFP-derived fluorescence is proportional to the 
number of GFP-expressing MDA-MB-231 cells injected, this data indicates that untreated and treated embryos 
had a similar number of surviving cancer cells. Injected embryos untreated or treated with 2-O-Bn-InsP5 were 
imaged by high resolution confocal microscopy and Z-stack scans were used to visualise cherry-positive blood 
vessels and GFP-positive MDA-MB-231 (Fig. 6E top and middle panels). Then, we used Imaris software to generate 
3D-rendered projections of the embryos vasculature and to exclude background green fluorescence observed in 
the yolk sack and gut before quantifying metastases number and volume (Fig. E bottom panels). Implantation 
of MDA-MB-231 breast cancer cell in zebrafish embryos resulted in widespread tumour cell dissemination and 
Figure 5. 2-O-Bn-InsP5 inhibits cell migration in different cell lines. (A) Results from fibronectin-induced 
migration of MDA-MB-231 cells assessed by Transwell assays in the presence of 2-O-Bn-InsP5 or InsP5 (50 μ M). 
Control cells were treated with vehicle alone. (B) MDA-MB-231 cells were pre-treated with the indicated 
concentrations of 2-O-Bn-InsP5. Control cells were pre-treated with H2O as control. Fibronectin-induced 
migration of MDA-MB-231 cells was assessed by Transwell assays. (C,D) Results from invasion of the indicated 
cancer cell lines assessed using transwell inserts pre-coated with Matrigel. Cells were treated with 2-O-Bn-InsP5, 
InsP5 (50 μ M) or vehicle control. (E) Invasion of A375M transfected with siRNA targeting PLCγ 1 (si-PLCγ 1) or 
with a control non-targeting siRNA (si-control) untreated or treated with 2-O-Bn-InsP5 50 μM. In all panels 
data indicate the number of migrated or invaded cells/field and are expressed as percentage of control, vehicle-
treated cells. Data are means ± SEM from n = 3 independent experiments. *p≤ 0.01; **p≤ 0.003; ***p≤ 0.001.
www.nature.com/scientificreports/
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metastasis at 5dpf (Fig. 6E–G). Treatment with 2-O-Bn-InsP5 significantly reduced the average volume of metas-
tasis compared to untreated embryos (Fig. 6E,F) and the number of disseminated metastasis (Fig. 6E,G). Similar 
results were obtained when GFP-expressing MDA-MB-231 cells were injected in the perivitelline cavity of 48 h 
post fertilization embryos (Fig. 6H). These results demonstrate for the first time that 2-O-Bn-InsP5 prevents 
MDA-MB-231 cells from disseminating and support the conclusion that inhibition of the novel PDK1/PLCγ 1 
pathway may represent a novel anti-metastatic strategy.
Discussion
Several lines of evidence from different groups including our own have indicated that inhibition of PLCγ 1 may 
represent a promising strategy to block metastasis spread. In particular, we previously demonstrated that down-
regulation of PLCγ 1 expression was able to revert metastasis formation in nude mice4. These data strongly sup-
ported the conclusion that PLCγ 1 inhibition has therapeutic potential to counteract metastasis dissemination 
and growth4. Despite this evidence and further data indicating that PLCγ 1 has a key role in tumourigenesis3,6,12, 
the development of selective inhibitors has proven problematic since phospholipases in general are not very good 
pharmacological targets6,23. In our quest for inhibitors of PLCγ 1 signalling we devised a strategy based on defin-
ing the signalling pathway and the interacting partners of PLCγ 1 rather than specifically targeting this phospholi-
pase. This led us to the discovery for PDK1 as a novel PLCγ 1 interacting protein17 involved in the activation of the 
Figure 6. 2-O-Bn-InsP5 inhibits MDA-MB-231 cells dissemination in zebrafish xenotransplant.  
(A) Representative tracks showing the swimming behaviour of 6dpf embryos, untreated or treated with 
2-O-Bn-InsP5 (100 μ M) and corresponding quantification (B) of the locomotor activity measured. Graph 
shows the average of the total distance ± SEM covered by each embryos (n = 15 untreated; n = 16 treated). 
(C) Representative image of 48 h post fertilisation Tg(kdrl:HsHRAS-mCherry)s896 zebrafish embryos injected 
with MDA-MB-231 cells stably expressing GFP. Embryos express Cherry fluorescent protein specifically in 
endothelial cells. Arrows indicate the injected cancer cells into the cardiac chamber. Arrowheads indicate the 
heart. (D) Zebrafish embryos injected with MDA-MB-231 and treated with or without 2-O-Bn-InsP5 (100 μ M)  
immunostained using anti-Cherry and anti-GFP antibodies and imaged by high resolution confocal 
microscopy. GFP-derived fluorescence was quantified in maximal z-stack projections of untreated and treated 
embryos (untreated n = 7; treated n = 7). (E) Image shows maximal z-stack projections and 3D-rendered 
surface of the vasculature (red) of zebrafish embryos and metastasis (green) in control and treated embryos. 
Implantation of MDA-MB-231 cells in zebrafish embryos resulted in widespread tumour cell dissemination 
and metastasis at 5dpf (white arrows). (F,G) The volume of metastasis and number of disseminated tumour 
cells (DTC) were evaluated using Imaris. Graphs indicate means ± SEM from n = 6 control and n = 10 treated 
embryos. Asterisks indicate **P value ≤ 0.01. (H) MDA-MB-231 cells stably expressing GFP were injected into 
the perivitelline cavity of 48 h zebrafish embryos. 2-O-Bn-InsP5 (100 μ M) was added 3 h after injection into the 
marine salt water. Graph shows the number of DTC counted at 5dpf and indicates means± SEM from n = 10 
control and n = 7 treated embryos.
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phospholipase and in the regulation of PLCγ 1-dependent cellular functions, including cell invasion. Consistent 
with a role for PDK1 in tumorigenesis, PDK1 overexpression and increased copy number in breast cancer has 
been shown to correlate with upstream lesions such as PTEN loss, PIK3CA mutation and EGFR amplification, 
and resulted in increased tumour growth, cell motility and poor prognosis13. Our previous study further suggests 
a major role for PDK1 in controlling metastasis development and progression by promoting PLCγ 1 activation17, 
strengthening the notion that PDK1 is an important potential target to develop novel anti-cancer strategies12,14. 
In this scenario the novel PDK1/PLCγ 1 interaction might play an important role and could be an important 
therapeutic target for metastasis.
We anticipated the targeting of PDK1/PLCγ 1 interaction at the plasma membrane to be an efficient strategy 
to counteract PLCγ 1 activation. Therefore, we aimed at designing an allosteric inhibitor that would specifically 
impair PDK1 plasma membrane localisation (rather than targeting its kinase domain) by interfering with its PH 
domain binding. We predicted that this approach would also lead to the finding of more tumour-specific and less 
toxic inhibitors. Structural analysis determined that PDK1 PH domain has an unusually spacious ligand binding 
site compared to other PtdIns(3,4,5)P3-binding PH domains18. In particular, PDK1 PH domain presents addi-
tional space around the D2- and D6-hydroxyl groups, which potentially could accommodate further phosphate 
groups. Thus, in addition to binding the PtdIns(3,4,5)P3 head group, PDK1 PH domain could also bind to the 
soluble inositols InsP5 and InsP6. 2-O-Bn-InsP5 was designed to exploit the peculiar PDK1-PH domain structure 
in order to reach high specificity. ITC experiments show that 2-O-Bn-InsP5 binds to PDK1-PH domain but not to 
AKT2-PH domain suggesting that 2-O-Bn-InsP5 inhibits specifically PDK1 activation by direct binding to its PH 
domain (Fig. 2). In agreement, PDK1 is inhibited with high selectivity by 2-O-Bn-InsP5 in a SelectScreen kinase 
profiling service21.
Here we show for the first time that 2-O-Bn-InsP5 targets the recently discovered PDK1-dependent PLCγ 1 
activation17 by impairing PDK1 and PLCγ 1 plasma membrane localisation and the formation of the PDK1/PLCγ 
1 complex required for the PDK1-dependent PLCγ 1 phosphorylation and activation (Figs 3 and 7). 2-O-Bn-InsP5 
treatment reduced PDK1/PLCγ 1 complex formation as shown by FRET and co-immunoprecipitation anal-
yses (Fig. 3). More importantly, we show that the 2-O-Bn-InsP5-mediated inhibition of PDK1/PLCγ 1 com-
plex assembly results in inhibition of cancer cell migration, invasion and in vivo dissemination using zebrafish 
xenotransplants (Fig. 6). Together these results strongly suggest that the blockade of PDK1/PLCγ 1 interaction by 
2-O-Bn-InsP5 is sufficient to inhibit cell invasion (Fig. 7). However, our results do not rule out the possibility that 
2-O-Bn-InsP5 might act via other PDK1 targets beside PLCγ 1. Therefore, it remains to be determined whether 
2-O-Bn-InsP5 could affect these or other biological functions also by targeting additional effectors in addition to 
Figure 7. Schematic representation of the potential mechanism by which 2-O-Bn-InsP5 inhibits the 
PDK1-dependent PLCγ1 activation. EGF induces phosphorylation of EGF receptor and activation of PI3Ks 
which catalyse the synthesis of PtdIns(3,4,5)P3 (PIP3). PIP3 in turn recruits the protein complex PDK1/PLCγ 
1 to the plasma membrane where PLCγ 1 is activated in a mechanism involving phosphorylation of its residue 
Tyr783. Recruitment of the protein complex and PLCγ 1 activation stimulate cell migration, invasion and 
metastasis dissemination. By competing with PIP3 for the binding to PDK1 PH domain, 2-O-Bn-InsP5 prevents 
the formation of PDK1/PLCγ 1 complex and the recruitment of both proteins to the plasma membrane. Thus 
2-O-Bn-InsP5 inhibits PLCγ 1 phosphorylation and activity and reduces tumour cell migration and metastasis 
dissemination. Yellow dots are phosphate groups bound to the inositol ring.
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PDK1- or PLCγ 1-dependent effectors. Altogether our data show for the first time that the PDK1/PLCγ 1 inter-
action is pharmacologically targetable and that its inhibition may have anti-metastatic effects in vivo. Therefore, 
2-O-Bn-InsP5 could potentially be a promising anti-cancer lead compound to design novel anti-metastatic drugs. 
Allosteric compounds have emerged as an attractive new class of small molecule inhibitors in cancer. Due to their 
specific mode of interaction that does not involve competition with ATP at the active site, they have been shown 
to be highly selective. We were among the first to suggest that activation of proteins involved in cell growth and 
tumourigenesis could be inhibited by interfering with their translocation to the plasma membrane24. In particular 
we showed that cytoplasmatic inositol phosphates could compete with PtdIns(3,4,5)P3 for the binding to AKT 
PH domain preventing its translocation to the plasma membrane and activation24 thus representing an important 
alternative to the use of inhibitors directly targeting the catalytic domain24. Recent work has reinforced the idea 
that small molecule inhibitors can act by interfering with the localization of proteins with key roles in cancer 
progression25,26. For instance, although the cancer-associated protein KRAS had long been considered undrug-
gable, a novel strategy was recently developed based on the indirect inhibition of its membrane localization26,27. 
In this respect results from our current work provide further support to the conclusion that inhibition of protein 
membrane translocation can represent a useful alternative strategy to block protein activation and ultimately 
processes associated with tumorigenesis. By binding to PDK1 PH domain, the allosteric inhibitor 2-O-Bn-InsP5 
inhibits PDK1 and PLCγ 1 membrane localisation and the PDK1/PLCγ 1 complex formation required for full 
PLCγ 1 activation. Thus, the allosteric PDK1 inhibitor 2-O-Bn-InsP5 targets PDK1 activity with a different mech-
anism of action than currently available ATP competitive inhibitors like GSK2334470. Because 2-O-Bn-InsP5 
interferes with membrane localisation of PDK1 and PLCγ 1 (Fig. 3) it could be speculated that 2-O-Bn-InsP5 
could selectively inhibit activation of PDK1 substrates by interfering with PDK1 (and its substrates) localisation 
to the plasma membrane. Since PDK1 has been shown to be a master regulator at the hub of many downstream 
signalling pathways, the effect of an allosteric inhibitor that would interfere with specific downstream substrates 
activation by modulating PDK1 spatial localization would be of great value allowing for the selective inhibition 
of some of the PDK1 signalling over others. Taken together, our findings show that 2-O-Bn-InsP5 could lead to 
the development of distinct more selective (hence less toxic) therapeutic strategies by targeting specifically the 
PDK1/PLCγ 1 complex formation at the plasma membrane and its downstream pathways that may lead to the 
development of novel drugs capable of selectively inhibiting the invasive potential of cancer cells.
Materials and Methods
Reagents and antibodies. Chemicals were purchased from Sigma-Aldrich, UK. Human PDGF was pur-
chased from R&D Systems. Recombinant EGF was purchased from Peprotech, UK. Antibodies were purchased as 
follows: pAKT (Thr308), pAKT (Ser473), pPLCγ 1 (Y783), total AKT and PDK1, pERK1/2 T202/Y204 and total 
ERK1/2 from Cell Signaling Technology, GAPDH from Abcam, PLCγ 1 from Santa Cruz Biotechnology. Glass-
bottomed 35-mm dishes were obtained from MatTek Corporation. InsP5 and 2-O-Bn-InsP5 were synthesised 
as previously reported21,28. Each compound was purified to homogeneity by ion-exchange chromatography on 
Q-Sepharose Fast Flow resin and used as the triethylammonium salt, which was fully characterized by 31P and 1H 
spectroscopy and accurately quantified by total phosphate assay.
Cell Culture and Transfections. MDA-MB-231, MDA-MB-435, 4T1 and NIH 3T3 cells lines were obtained 
from the American Type Culture Collection (Manassas, VA, USA). TSA were provided by Dr. P. Lollini, Istituto 
di Cancerologia, University of Bologna, Italy, and A375M were provided by Dr Daniele Bergamaschi, QMUL, 
UK. MDA-MB-231 were cultured in DMEM (Life Technologies, UK); MDA-MB-435, 4T1, TSA and A375M 
were cultured in RPMI 1640 (Life Technologies or PAA, UK) supplemented with 10% (v/v) Foetal Bovine Serum 
(FBS), Sodium Pyruvate 1% (v/v), 1X L-glutamine/penicillin/streptomycin and 0.1% gentamycin (v/v). NIH 
3T3 cells were maintained in DMEM containing 10% donor calf serum. NIH 3T3 cells were transfected with 
1 μ g of DNA encoding for eGFP-Akt, eGFP-Akt-mRFP or eGFP-PDK129 using Lipofectamine LTX with PLUS 
reagent (Life Technologies) in OptiMEM containing GlutaMAX (Life Technologies), as recommended by the 
manufacturer. MDA-MB-231 cells were co-transfected with pOZ-PDK1 and PRK5-PLCγ 1 using Lipofectamine 
(Life Technologies) according to the manufacturer’s instructions. siRNA transfection was performed by using 
Hiperfect (Qiagen, UK) for A375M as previously described17. SMARTpool siRNA targeting PLCγ 1 were pur-
chased from Dharmacon, USA whilst the non-targeting siRNA (Silencer® Negative Control #1 siRNA) was pur-
chased from Applied Biosystems.
Cell migration and Matrigel invasion assay. MDA-MB-231, MDA-MB-435, TSA, 4T1 and A375M cell 
lines were serum starved overnight before the experiment. Cell migration and invasion assays were performed as 
described17,30. Briefly, cells were left untreated or pre-treated with 50 μ M of 2-O-Bn-InsP5 for 30 minutes before 
being detached, counted and plated on inserts. For migration assays, a suspension of 10,000 cells in 150 μ l was 
homogenously added in the upper chamber and the lower chamber was filled with RPMI or DMEM containing 
0.5% BSA. Cells were allowed to migrate for 4 hours at 37 °C, 5% CO2 in the absence or presence of the inhibitor. 
For invasion assay, Matrigel pre-coated inserts (8.0 μ m pores, 10 mm diameter, BD Bioscience, UK) were used. 
Inserts were re-hydrated for 1 hour in DMEM or RPMI 1640 according to the cell type before the experiment. A 
suspension of 10,000 cells (60,000 for MDA-MB-435) in 500 μ l was homogenously added in the upper chamber 
and the lower chamber was filled with RPMI or DMEM containing 10% FBS. Cells were allowed to invade for 
36 hours at 37 °C, 5% CO2 in the absence or presence of the inhibitor. Cells that did not migrate or invade were 
removed using a cotton bud whereas cells that had migrated or invaded were fixed with paraformaldehyde and 
stained with 0.1% crystal violet solution for 10 minutes. A Leica phase-light microscope using a 10X magnitude 
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objective was used for manual counting. A minimum of five fields was counted per insert. Each experiment was 
performed in duplicate and the average of cells/fields was calculated.
Intracellular Calcium Measurement. MDA-MB-231 and MDA-MB-435 were seeded on bottom-glassed 
chambers (Labtek, UK) and serum starved overnight. Cells were then incubated with HBSS (Life Technologies) 
containing 0.5% BSA, 2 mM CaCl2, 4 μ M Fluo-4-AM (Life Technologies) for 45 minutes at 37 °C, washed twice 
in HBSS 0.5% BSA 2mM CaCl2 and left in the same solution for 30 minutes for de-esterification of the Fluo-
4-AM dye. Where indicated 50 μ M InsP5 or 50 μ M 2-O-Bn-InsP5 were added during the de-esterification step 
for 30 minutes. Fluorescence was measured using the LSM 510 inverted confocal microscope equipped with a 
chamber for live imaging at 37 °C supplied with 5% CO2 using a 20X objective. After recording basal fluorescence, 
cells were then stimulated with EGF (20 ng/ml) and fluorescence was measured for 6 minutes before further 
stimulation with 1 mM ATP (Sigma, UK). Thirty cells were selected and variation of fluorescence intensity was 
analysed for each sample.
Lysis conditions and Western blotting analysis. After stimulation or treatment, NIH 3T3 were lysed 
for 5 min on ice in Lysis buffer [20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 100 mM NaF, 10 mM Na4P2O7, and 
10 mM EDTA supplemented with one complete protease inhibitor cocktail tablet (Roche) and 1% Triton X-100]. 
To terminate the reaction, SDS Sample buffer [125 mM Tris- HCl (pH 6.8), 6% SDS, 20% glycerol, and 0.02% bro-
mophenol blue supplemented with 10% β-mercaptoethanol] was added and the samples were boiled for 5 min. 
The proteins were separated on a NuPAGE 4 to 12% Bis-Tris Gel (Life Technologies) and transferred to a pol-
yvinylidene difluoride (PVDF) membrane (Immobilon FL, Millipore). For protein detection with the Odyssey 
Infrared Reader (LI-COR), membranes were incubated in blocking buffer (LI-COR) for 1 h, and incubated for 
24 h at 4 °C with antibodies against pAKT (Thr308) together with total AKT, or pAKT (Ser473) together with 
total AKT (each antibody diluted in blocking buffer at 1:1000). The infrared dye-conjugated secondary antibodies 
IRDye 800CW and 680LT (Rockland) were used at a 1:5000 dilution in blocking buffer for 1 h.
MDA-MB-231 were lysed in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 0.1% NP40, 
250 mM NaCl, and proteases inhibitors cocktail 2 (Sigma-Aldrich, UK). Lysates were then centrifuged at 
13,000 rpm for 10 min at 4 °C. Proteins were separated by SDS/PAGE and transferred to nitrocellulose. 
Membranes were incubated with a solution of 5% milk (w/v) and then incubated overnight with the diluted 
primary antibodies [pPLCγ 1(Y783) or GAPDH]. The appropriate peroxidase-conjugated secondary antibod-
ies (Sigma-Aldrich, UK) were used and proteins were detected by enhanced chemi-luminescence reaction (GE 
Healthcare, UK).
Phosphokinase antibody array. Following overnight starvation, MDA-MB-231 cells were left untreated 
or pre-treated with 50 μ M 2-O-Bn-InsP5 and then stimulated with 50 ng/ml EGF for 10 min in the presence or 
absence of the inhibitor. Cells were lysed as described above and phosphokinase antibody array was performed 
according to the manufacturer’s instructions (R&D Systems).
Co-immunoprecipitation. Four sets of three 4-cm Petri dishes of MDA-MB231 (two sets treated for one 
hour with 50 μ M 2-O-Bn-InsP5 and two sets treated with vehicle only) were stimulated with 50 ng/ml EGF for 
the indicated time point, then lysed in lysis buffer (50 mM Tris pH 8.0, 50 mM KCl, 1% NP-40) containing pro-
tease and phosphatases inhibitors (Sigma-Aldrich, UK). 3 μ g of anti-PLCγ 1 antibody (Santa Cruz Biotechnology, 
USA) or control mouse IgG were immobilised onto 30 μ l of magnetic protein G Dynabeads (Life Technologies) 
using the cross-linker Bis(sulfosuccinimidyl)suberate (BS3). Briefly, Dynabeads were incubated for 1 hour at RT 
with anti-PLCγ 1 antibody or control mouse IgG and then incubated for 30 minutes with BS3 conjugation buffer 
(5 mM BS3, 20 mM Sodium Phosphate, 0.15 M NaCl pH. 8.0). The crosslinking reaction was quenched by incu-
bating the Dynabeads with BS3 quenching buffer (1 M Tris HCl pH 7.5). Dynabeads were then resuspended in 
lysis buffer and used for immunoprecipitation. Lysates were cleared by centrifugation at 10,000 g for 3 minutes 
at + 4 °C. 2.5 mg of protein lysates were mixed with 30 μ l of Dynabeads previously cross-linked to anti-PLCγ 1 
antibody (Santa Cruz Biotechnology, USA) or control mouse IgG, and incubated overnight at + 4 °C. Beads were 
collected with a Dynabead magnet, washed three times with lysis buffer on a rotating wheel at 4 °C for 5 min, and 
resuspended in 50 μ l Laemmli sample buffer for SDS-PAGE and immunoblotting.
Confocal Microscopy Analysis. MDA-MB-231 cells were co-transfected with PRK5-PLCγ 1 and 
pOZ-PDK1. Twentyfour hours after transfection cells were serum deprived overnight. The following day, cells 
were left untreated or treated with 50 μ M 2-O-Bn-InsP5 for 30 minutes, stimulated with serum free DMEM con-
taining EGF (50 ng/ml) in the presence or absence of 50 μ M 2-O-Bn-InsP5 for the indicated times and then fixed 
in paraformaldehyde 4% (v/v) for 30 minutes at room temperature (RT). Cells were permeabilised with PBS 
containing 0.25% Triton-X-100 for 2.5 minutes at RT. Unspecific staining was prevented by blocking the cover-
slips with a solution of PBS/0.1% BSA for 30 minutes at RT. Coverslips were then incubated overnight with pri-
mary antibodies (anti-mouse-PLCγ 1 and anti-rabbit-PDK1 diluted 1:50 in PBS/0.1% BSA). Coverslips were then 
washed 3X with PBS/0.1% BSA, incubated with secondary antibodies anti-mouse-Alexa488 (Life Technologies) 
and anti-rabbit Alexa555 (Life Technologies) and analysed using a Carl Zeiss LSM 510 Meta confocal microscope 
using a Zeiss plan apochromat 63× 1.4 NA(oil) lens.
Translocation analysis. MDA-MB-231 co-transfected with PRK5-PLCγ 1 and pOZ-PDK1 were treated 
as for confocal microscopy analysis and coverslips were analysed using a Leica Epi-fluorescence microscope. 
MDA-MB-231 untreated or treated with 2-O-Bn-InsP5 (50 μ M) were stimulated with EGF (50 ng/ml) in the 
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absence or presence of 2-O-Bn-InsP5 (50 μ M). The number of cells displaying translocation of exogenous PLCγ 
1 and PDK1 to the membrane was manually counted and expressed as percentage. A minimum of 100 cells were 
counted for each condition per experiment in three independent experiments.
Time resolved FRET by multiple frequency domain FLIM. Cells were seeded at 150,000 per 35-mm 
glass-bottomed tissue culture dish (MatTek) and transfected as described earlier. After stimulation with PDGF 
(30 ng/ml) for 5 min, the cells were washed with PBS and then fixed in PBS containing 4% paraformaldehyde 
for 10 min. The dishes were washed with PBS and then mounted with Mowiol supplemented with 2.5% (w/v) 
1,4-diazabicyclo[2.2.2]octane (DABCO) at 4 °C. Time-resolved FRET was used to determine the variations in 
AKT conformation. The lifetime of the eGFP donor chromophore expressed as a fusion protein in the cells was 
acquired using the Lambert Instruments multiple frequency domain Fluorescence Lifetime Imaging Microscope 
(FLIM). The FRET efficiency (Ef) for all the pixels was calculated for each cell as: Ef = 1− (τ D+A/τ D), τ D being the 
phase lifetime of the donor (eGFP-AKT) and τ D+A the phase lifetime of the donor in presence of an acceptor 
(eGFP-AKT-mRFP). Details of the frequency domain FLIM, operation, acquisition parameters and data analysis 
have been detailed previously31.
Steady state FRET by Acceptor Photo-bleaching. Cells were treated as for confocal microscopy 
analysis. Cells were imaged with excitation λ = 488 nm and λ = 543 laser line and emission spectra were col-
lected respectively in two different channels of the PMT detector. Briefly, cells overexpressing PLCγ 1 or PDK1 or 
co-expressing PLCγ 1 and PDK1 were co-stained with Alexa-488 and Alexa-555 conjugated antibodies. The FRET 
efficiency was measured by acceptor photo-bleaching, as previously described17,32. A selected area of the cell was 
repeatedly photobleached with λ =  543 nm laser line at full power for 1 minute and FRET efficiency was measured 
as the increase (or dequenching) of donor fluorescence after photo-bleaching in the selected area. All fluorescence 
measurements were performed in MetaMorph software (Molecular Devices Inc., USA). Reference spectra were 
generated from coverslips incubated separately with the two Alexa-conjugated secondary antibodies alone in 
order to generate single positive sample and all data were corrected for cross-talk and background fluorescence. 
Percentage of FRET was calculated measuring donor fluorescence of 10 cells before and after acceptor bleaching.
Preparation of DNA constructs. The PH domains of human AKT2 [amino-acids 1-116] and human 
PDK1 [amino-acids 411-552] were PCR amplified using the oligos AKT2 PH-s: 5-g gat cct atg aat gag gtg tct gtc 
atc aaa gaa ggc-3 and AKT2 PH-a: 5-gaattc tca gcc tgg ggc ccg ctg ctt gag gc-3 and PDK1 PH-s: 5-g gat cct atg 
aac ata gag cag tac att cac gat-3 and PDK1 PH-a: 5-gaattc tca gtc cgg gtg gct ctg gta tcg ctg-3 respectively. The 
PCR products were subcloned BamHI-EcoRI into the vector pTriEX6-HIS-GST-3C, a modified version of the 
Novagen vector pTriEX-6 to create pTriEX6-GST-PH AKT2 and pTriEX6-GST-PH PDK1.
Preparation of the recombinant PH domains. BL21 (DE3) (100 μ l) were electroporated with 500 ng of 
either pTriEX6-GST-PH AKT2 or pTriEX6-GST-PH PDK1 plasmid DNA, recovered in 200 μ l of SOC medium 
and plated on ampicillin plates. A colony was picked and grown overnight in 5 ml L-Broth supplemented with 
100 μ g/ml of ampicillin at 37 °C in a shaking incubator. This starter culture was used to inoculate 2 × 200 ml 
L-Broth/ampicillin and allowed to grow at 37 °C with shaking. When the OD600nm reached approximately 0.5 the 
expression of the proteins was induced by addition of 1 mM IPTG. Cultures were allowed to grow overnight at 
20 °C in a shaking incubator.
The bacteria from each culture were pelleted by centrifugation and then lysed at 4 °C in 2 × 10 ml of lysis 
buffer comprised of Buffer A (50 mM Tris-HCl pH7.5; 150 mM NaCl; 1 mM EDTA; 5% glycerol) supplemented 
with 1% Triton X-100, 1 mM DTT, 10 mM β − Glycerophosphate, 1 mM NaF, 10 mM Benzamidine and com-
plete protease inhibitor cocktail (Roche). The re-suspended bacteria were sonicated (3 × 10 s at an amplitude 
of 10 microns at 4 °C) and centrifuged at 20,000 g for 10 min at 4 °C. The supernatant was subsequently added 
to glutathione-sepharose beads (1 ml bed volume) and incubated for 2 h. After extensive washing with Buffer 
A + 1 mM DTT the beads were re-suspended in 500 μ l of the same buffer and the PH domains cleaved from 
the beads by addition of 3C protease. Cleavage was allowed to occur overnight at 4 °C. The 1 ml total volume of 
cleaved PH domains were concentrated to 500 μ l using a Vivaspin 5,000 Da cut off concentrator and applied to a 
S75 size exclusion column equilibrated in the ITC Buffer comprising of Buffer A + 0.5 mM TCEP.
Isothermal Titration Calorimetry Experiments. The purified PH domains of PDK1 and AKT2 were 
adjusted to 45 μ M and 48 μ M respectively for the ITC experiments. The inhibitor 2-O-Bn-InsP5 was diluted 
with ITC buffer (see above) to a 10 fold higher concentration than the individual PH domains. ITC titrations 
were performed on a VP-ITC200 MicroCalorimeter (MicroCal) at 25 °C (unless otherwise stated) with 15 × 3 μ L 
injections of 2-O-Bn-IP5 into PH domain located in the cell. Subtraction of the heats of dilution, integration of 
the raw data and subsequent fitting to a one site binding model was carried out using the Origin (version 7) soft-
ware supplied with the instrument.
Zebrafish xenotransplant. Zebrafish (Danio rerio) were handled in compliance with local animal care 
regulations and standard protocols. All experiments were performed in accordance with relevant guidelines and 
regulations and were subject to local ethics approval and done in accordance with the Animals (Experimental 
Procedures) Act, 1986, under license from the United Kingdom Home Office. The QMUL Ethics Committee 
approved our experiments and all procedures are done in accordance with the UK Home Office Licensing (PPL 
70/7452). Fish were kept at 28 °C in aquaria with day/night light cycles (10-hour dark/14-hour light periods). 
The developing embryos were kept in an incubator at constant temperature. At 48 h post-fertilization, zebrafish 
embryos were dechorionated with sharp forceps (Dumont Tweezers #5, World Precision Instruments Ltd, UK) 
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and anesthetized with 0.04  mg/ml of tricaine (MS-222, Sigma). Anesthetized embryos were then transferred into 
a 1% agarose gel for microinjection.
For injection into the heart22, 50–100 cells, manually counted, were injected above the ventral end of the duct 
of Cuvier where it opens into the heart using a manual injector (Picospritzer III, Parker Hannifin Instruments). 
After injection, the zebrafish embryos were briefly imaged using a Leica SPE confocal microscope. Embryos dis-
playing a similar number of injected cells were selected and divided into a control (untreated) group and treated 
group (incubated in marine salt water supplemented with 100 μ M 2-O-Bn-InsP5). Embryos were then immedi-
ately transferred into an incubator set at 35 °C to compromise between the optimal temperature requirements 
for fish and mammalian cells. Three days after injection zebrafish embryos were immunostained with rabbit 
anti-GFP (MBL) and chicken anti-RFP (MBL) followed by staining with Alexa-conjugated goat anti rabbit and 
goat anti chicken antibodies (Life Technologies) and imaged with a Zeiss LSM 710 Scanning Confocal Microscope 
using a 20x objective. 3D-rendered models of zebrafish embryos were generated with Imaris (Bitplan AG) 
using tiled z-stacks of 15–20 confocal slices. Dimensional analysis of metastases was carried out using the 
surface rendering function of Imaris based on the GFP signal throughout the tiled z-scan series. GFP signal 
detected within the vessel was excluded by generating a mask based on the mCherry signal within the blood 
vessels. Autofluorescence from the yolk sac and signal from the intestine was excluded. The number and the 
volume of metastasis were measured in n = 6 control and n = 10 treated embryos from 2 independent experi-
ments. Experiments were discarded when the survival rate of the control group was < 90%. Alternatively ~300 
cells were resuspended in PBS and 1–5 nL of tumour cells solution were injected into the perivitelline cavity 
of each embryo33 using a manual injector (Picospritzer III, Parker Hannifin Instruments). After injection, the 
fish embryos were immediately transferred into 35 °C incubator and examined every day for monitoring tumor 
dissemination using a fluorescent microscope. Three separate experiments were performed. Counting of dissem-
inated cells was done using a Zeiss Axioplan epifluorescence microscope and disseminated cells counted under 
high magnification.
Zebrafish locomotor activity assay. We assayed 6dpf untreated embryos (n = 15), or treated with 
2-O-Bn-InsP5 (n = 16) for their locomotor activity. Larvae were raised at 28 °C on a 14/10 h light/dark cycle. 
Embryos were fed on day 5, and morning of day 6. Two hours before the behavioural procedure, embryos were 
transferred to a clean plate with no food, and were then moved to the behavioural room. For each trial, 4 embryos 
were transferred to a tank (11.2 × 7.5 × 2.0 cm) containing 4 insets (6.8 × 2.2 × 2.0 cm) with opaque walls, each 
with 15 mL of water. The tank was placed inside a Zebrabox (ViewPoint Life Sciences) that was continuously illu-
minated with infrared and white lights. The swimming behaviour of each fish was monitored for 10 minutes using 
an automated video-tracking system (Zebralab, ViewPoint Life Sciences), and the movement of each larva was 
recorded using the Zebralab tracking quantization mode. The Zebralab tracking quantification thresholds were set 
in the following way: detection threshold, 120 (color transparent); movement threshold: high-speed, 6.0 mm/sec 
and inactivity, 2.0 mm/sec; bin size, 60 s. Red and green tracking lines in Fig. 6G correspond to high-speed and 
slow-speed trajectories, respectively. Locomotor activity was quantified based on the total distance covered by 
each fish.
Statistical analysis. A nonparametric Mann-Whitney test was used to compare the medians of the two 
data sets for the FLIM data with GraphPad Prism software. To interpret the distribution of data, we used box and 
whiskers plots. The box and whiskers plot is a histogram-like method for displaying upper and lower quartiles 
and maximum and minimum values in addition to the median. Each red symbol represents the FRET efficiency 
of one cell. For the Zebrafish tumor experiments and the locomotor activity assay a two-tailed, unequal variance 
Student’s t-test was used.
In all the other experiments statistical analyses was performed using the one-tailed, paired Student’s t-test.
References
1. Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9, 274–284, 
doi: 10.1038/nrc2622 (2009).
2. Kassis, J., Lauffenburger, D. A., Turner, T. & Wells, A. Tumor invasion as dysregulated cell motility. Semin Cancer Biol 11, 105–117, 
doi: 10.1006/scbi.2000.0362 (2001).
3. Wells, A., Grahovac, J., Wheeler, S., Ma, B. & Lauffenburger, D. Targeting tumor cell motility as a strategy against invasion and 
metastasis. Trends Pharmacol Sci 34, 283–289, doi: 10.1016/j.tips.2013.03.001 (2013).
4. Sala, G. et al. Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 68, 10187–10196, doi: 
10.1158/0008-5472.CAN-08-1181 (2008).
5. Raimondi, C. & Falasca, M. Phosphoinositides signalling in cancer: focus on PI3K and PLC. Adv Biol Regul 52, 166–182, doi: 
10.1016/j.advenzreg.2011.09.016 (2012).
6. Park, J. B. et al. Phospholipase signalling networks in cancer. Nat Rev Cancer 12, 782–792, doi: 10.1038/nrc3379 (2012).
7. Falasca, M. et al. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO 
J 17, 414–422, doi: 10.1093/emboj/17.2.414 (1998).
8. Piccolo, E. et al. The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene 21, 
6520–6529, doi: 10.1038/sj.onc.1205821 (2002).
9. Maffucci, T. et al. A phosphoinositide 3-kinase/phospholipase Cgamma1 pathway regulates fibroblast growth factor-induced 
capillary tube formation. Plos One 4, e8285, doi: 10.1371/journal.pone.0008285 (2009).
10. Falasca, M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr 
Pharm Des 16, 1410–1416 (2010).
11. Wong, K. K., Engelman, J. A. & Cantley, L. C. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 20, 87–90, doi: 
10.1016/j.gde.2009.11.002 (2010).
12. Raimondi, C. & Falasca, M. Targeting PDK1 in cancer. Curr Med Chem 18, 2763–2769 (2011).
13. Maurer, M. et al. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway 
in breast carcinoma. Cancer Res 69, 6299–6306, doi: 10.1158/0008-5472.CAN-09-0820 (2009).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 6:26142 | DOI: 10.1038/srep26142
14. Fyffe, C. & Falasca, M. 3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer. 
Cancer Manag Res 5, 271–280, doi: 10.2147/CMAR.S35026 (2013).
15. Primo, L. et al. Essential role of PDK1 in regulating endothelial cell migration. J Cell Biol 176, 1035–1047, doi: 10.1083/jcb.200607053 
(2007).
16. Pinner, S. & Sahai, E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 10, 127–137, 
doi: 10.1038/ncb1675 (2008).
17. Raimondi, C., Chikh, A., Wheeler, A. P., Maffucci, T. & Falasca, M. A novel regulatory mechanism links PLCgamma1 to PDK1. J Cell 
Sci 125, 3153–3163, doi: 10.1242/jcs.100511 (2012).
18. Komander, D. et al. Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J 23, 
3918–3928, doi: 10.1038/sj.emboj.7600379 (2004).
19. Piccolo, E. et al. Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene 23, 1754–1765, doi: 
10.1038/sj.onc.1207296 (2004).
20. Maffucci, T. et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in 
antiangiogenic and antitumor effects. Cancer Res 65, 8339–8349, doi: 10.1158/0008-5472.CAN-05-0121 (2005).
21. Falasca, M. et al. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J 
Cancer 102, 104–114, doi: 10.1038/sj.bjc.6605408 (2010).
22. He, S. et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol 
227, 431–445, doi: 10.1002/path.4013 (2012).
23. Lattanzio, R., Piantelli, M. & Falasca, M. Role of phospholipase C in cell invasion and metastasis. Adv Biol Regul 53, 309–318, doi: 
10.1016/j.jbior.2013.07.006 (2013).
24. Berrie, C. P. & Falasca, M. Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic 
intervention. FASEB J 14, 2618–2622, doi: 10.1096/fj.00-0096hyp (2000).
25. Ferrari-Amorotti, G. et al. Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. Cancer Res 
73, 235–245, doi: 10.1158/0008-5472.CAN-12-1739 (2013).
26. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 
497, 638–642, doi: 10.1038/nature12205 (2013).
27. Baker, N. M. & Der, C. J. Cancer: Drug for an ‘undruggable’ protein. Nature 497, 577–578, doi: 10.1038/nature12248 (2013).
28. Godage, H. Y., Riley, A. M., Woodman, T. J. & Potter, B. V. L. Regioselective hydrolysis of myo-inositol 1,3,5-orthobenzoate via a 
1,2-bridged 2′ -phenyl-1′ ,3′ -dioxolan-2′ -ylium ion provides a rapid route to the anticancer agent Ins(1,3,4,5,6)P5. Chem Commun 
(Camb), 2989–2991, doi: 10.1039/b605392k (2006).
29. Calleja, V. et al. Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. Plos Biol 5, e95, doi: 
10.1371/journal.pbio.0050095 (2007).
30. Falasca, M., Raimondi, C. & Maffucci, T. Boyden chamber. Methods Mol Biol 769, 87–95, doi: 10.1007/978-1-61779-207-6_7 (2011).
31. Masters, T. A. et al. Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells. Sci 
Signal 3, ra78, doi: 10.1126/scisignal.2000738 (2010).
32. Guillaud, L., Wong, R. & Hirokawa, N. Disruption of KIF17-Mint1 interaction by CaMKII-dependent phosphorylation: a molecular 
model of kinesin-cargo release. Nat Cell Biol 10, 19–29, doi: 10.1038/ncb1665 (2008).
33. Nicoli, S., Ribatti, D., Cotelli, F. & Presta, M. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer 
Res 67, 2927–2931, doi: 10.1158/0008-5472.CAN-06-4268 (2007).
Acknowledgements
The authors would like to thank the zebrafish facility within the School of Biological and Chemical Sciences at 
QMUL for zebrafish care and Dr. Gaia Gestri and Dr. Ricardo M. Neto-Silva based at the Department of Cell and 
Developmental Biology, University College London for helping with the zebrafish experiments. We are grateful 
to Dr. Roger George and Dr. Svend Kjaer from the Protein Synthesis Laboratory at LRI for their advice and 
guidance in the ITC measurements. We also thank Dr. P. Lollini, Istituto di Cancerologia, University of Bologna, 
Italy, Dr Daniele Bergamaschi, QMUL, UK for providing TSA and A375M cells respectively and Dr. Massimo 
Broggini, Oncology Department, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Italy for providing 
MDA-MB-231 stably expressing GFP for the xenotransplant zebrafish experiment. This work was supported 
in part by grants from Pancreatic Cancer Research Fund and Prostate Cancer UK (Project Grant PG12-23 to 
M.F.). We thank the Wellcome Trust for support (Programme Grant 082837 to A.M.R. and B.V.L.P.). B.V.L.P. 
is a Wellcome Trust Senior Investigator (Grant 101010). The work in Cell Biophysics was supported by Cancer 
Research UK (V.C. and B.L.).
Author Contributions
C.R., B.L. and M.F. designed research. C.R. and M.F. designed, coordinated and carried out the bulk of the 
experiments. V.C. and B.L. designed and carried out experiments of PH domain binding. T.M. contributed to 
in vitro experiments. C.R., R.F., A.F., C.H.B. and M.F. designed and carried out the zebrafish experiments. A.M.R. 
and B.V.L.P. designed and executed the synthesis of 2-O-Bn-InsP5. C.R., B.L., T.M. and M.F. wrote the manuscript. 
C.R., A.F., A.M.R. and B.V.L.P. edited the manuscript. M.F. conceived the project, led and supervised the study. All 
authors read and approved the final manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Raimondi, C. et al. A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks 
Breast and Melanoma Cancer Cell Invasion. Sci. Rep. 6, 26142; doi: 10.1038/srep26142 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
